Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share news that the company has established the optimum peak stimulation period of 6 hours for neuron outgrowth by AP-188 or DMT. The increased growth was achieved with a sub-hallucinogenic dose.

Mr. Moreau also explains that this current data set is from the second part of their in-vitro experiment designed to focus on the duration of infusion needed to achieve maximal cortical neuron outgrowth. The data showed that an increase in growth of over 40% was observed in the group treated for 6 hours with 30 nM DMT.